Description

A safety review was carried out by Health Canada to evaluate the increased risk of heart failure with the use of DPP-4 inhibitors as a follow-up to a risk communication released by the U.S. FDA stating that saxagliptin and alogliptin might increase the risk of heart failure, in particular in patients who have other risk factors for heart failure. The product safety information in the U.S. and Canada were recently updated to include this risk.

Resources

Name	Format	Description	Link
Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure	HTML		https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-dipeptidylpeptidase-4-inhibitors-assessing-potential-risk-heart-failure.html
Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure	HTML		https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/examens-innocuite/resume-de-examen-de-innocuite-inhibiteurs-dipeptidylpeptidase-4-evaluation-risque-potentiel-insuffisance-cardiaque.html

Tags

Topics

Categories